CARLOS QUIROS: Open Payments
NPI 1679502884 · BONITA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$960 in 41 payments from 12 companies in 2025. Trend: 2023 $300 · 2024 $426 · 2025 $960
Food & beverage: $960
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 7 | $239 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $156 |
| Novo Nordisk Inc | 11 | $141 |
| Abbott Laboratories | 4 | $90 |
| GlaxoSmithKline, LLC. | 3 | $89 |
| Lilly USA, LLC | 3 | $72 |
| AstraZeneca Pharmaceuticals LP | 1 | $54 |
| SANOFI-AVENTIS U.S. LLC | 2 | $35 |
| ViiV Healthcare Company | 1 | $35 |
| Organon LLC | 1 | $19 |
Products named: JARDIANCE, Yeztugo, FREESTYLE LIBRE 3, Ozempic, MOUNJARO, AREXVY, AIRSUPRA, Wegovy.
Industry payments across CA — which companies pay providers there.
